JP2024523822A5 - - Google Patents

Info

Publication number
JP2024523822A5
JP2024523822A5 JP2023574858A JP2023574858A JP2024523822A5 JP 2024523822 A5 JP2024523822 A5 JP 2024523822A5 JP 2023574858 A JP2023574858 A JP 2023574858A JP 2023574858 A JP2023574858 A JP 2023574858A JP 2024523822 A5 JP2024523822 A5 JP 2024523822A5
Authority
JP
Japan
Prior art keywords
indole
ethyl
fluoro
amine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523822A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032000 external-priority patent/WO2022256554A1/en
Publication of JP2024523822A publication Critical patent/JP2024523822A/ja
Publication of JP2024523822A5 publication Critical patent/JP2024523822A5/ja
Pending legal-status Critical Current

Links

JP2023574858A 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 Pending JP2024523822A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195943P 2021-06-02 2021-06-02
US63/195,943 2021-06-02
US202163288313P 2021-12-10 2021-12-10
US63/288,313 2021-12-10
PCT/US2022/032000 WO2022256554A1 (en) 2021-06-02 2022-06-02 Fluorinated tryptamine compounds, analogues thereof, and methods using same

Publications (2)

Publication Number Publication Date
JP2024523822A JP2024523822A (ja) 2024-07-02
JP2024523822A5 true JP2024523822A5 (enExample) 2025-06-03

Family

ID=84324579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574858A Pending JP2024523822A (ja) 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法

Country Status (11)

Country Link
US (1) US20240286998A1 (enExample)
EP (1) EP4347559A4 (enExample)
JP (1) JP2024523822A (enExample)
KR (1) KR20240017363A (enExample)
AU (1) AU2022287013A1 (enExample)
BR (1) BR112023025340A2 (enExample)
CA (1) CA3220850A1 (enExample)
CO (1) CO2023018652A2 (enExample)
IL (1) IL308944A (enExample)
MX (1) MX2023014437A (enExample)
WO (1) WO2022256554A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
US20250091993A1 (en) * 2022-01-27 2025-03-20 Terran Biosciences Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine
WO2025052388A1 (en) * 2023-09-07 2025-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Psychedelic compounds, methods of their preparation and uses thereof
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223239A1 (en) * 1995-06-06 1996-12-12 Schering Corporation Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
US6800637B2 (en) * 2002-09-12 2004-10-05 Wyeth Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
EP3793360A4 (en) * 2018-05-16 2022-02-16 University of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
KR20260008838A (ko) * 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
AU2021337466A1 (en) * 2020-09-01 2023-03-30 Enveric Biosciences Canada Inc. Halogenated psilocybin derivatives and methods of using
AU2021343525A1 (en) * 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
JP2023553094A (ja) * 2020-12-07 2023-12-20 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体

Similar Documents

Publication Publication Date Title
JP2024523822A5 (enExample)
JP2012521428A5 (enExample)
RU2012142180A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств
JP2009504763A5 (enExample)
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
MD3452448T2 (ro) Modulatori ai răspunsului integrat la stres
WO2006096435A1 (en) Pharmaceutical compositions for the treatment and/or prevention of depression
JP2011527683A5 (enExample)
JP2012521429A5 (enExample)
JP2021512098A5 (enExample)
JPH08208471A (ja) 薬物反応の増強作用
JP2014502641A5 (enExample)
JP2007508360A5 (enExample)
JP2007532546A5 (enExample)
CN103402514A (zh) 用于治疗运动障碍的血清素受体激动剂组合物
RU2013108258A (ru) Применение разагилина для лечения обонятельной дисфункции
JP2019014762A (ja) ニロチニブ塩酸塩の多形形態
JP2022501434A5 (enExample)
TW201804994A (zh) 抗真菌劑
JP2022541938A5 (enExample)
US12226386B2 (en) Compositions and methods for treating biofilms
JP2014518212A5 (ja) 化合物及び組成物
JP2016538306A5 (enExample)
US12576083B2 (en) Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer